Baicheng Pharmaceutical (301096.SZ): Innovative drug BIOS0635-048 tablets approved for clinical trials

Zhitong Finance App News, Baicheng Pharmaceutical (301096.SZ) issued an announcement. The innovative drug BIOS0635-048 tablets independently developed by the company obtained the National Drug Administration (NMPA) clinical trial approval notice, agreeing to conduct clinical trials of this single drug in advanced solid tumors.

BIOS0635-048 tablets are novel small molecule inhibitors independently developed by the company and intended for the treatment of various solid tumors. BIOS0635-048 tablets act on epigenetic targets closely related to the occurrence and development of various tumors. They can inhibit endocrine receptors at the transcriptional level and overcome resistance to endocrine therapy. Additionally, the drug can also regulate cell cycle and MYC levels, providing new treatment options for patients with solid tumors. Currently, no drug targeting this target has been approved for marketing in the world. The registered classification of this product is chemical class 1.